PURA Credits Kali-Extracts (USOTC: KALY) Instrumental Role In Cannabis Beverage Sales Growth
Dallas, TX -- April 24, 2019 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) (“PURA”) today issued a statement crediting Kali-Extracts (USOTC: KALY) role in PURA’s cannabis beverage sales growth to date and going forward. PURA yesterday released a management presentation offering detail and insight into the company’s recently published 2018 financial statement and plans for ongoing growth in 2019. In its 2018 financial statement, the company reported over $1.2 million in revenue for year-end December 31, 2018 with over $500,000 in net profit. The 2018 revenue grew 350% compared to 2017. The company’s primary business is producing cannabis beverages. PURA has licensed KALY’s patented cannabis extraction processes as the sole licensee for cannabis infused beverages. “The KALY patented extraction process has empowered PURA to have what we believe to be the most clear CBD infused beverage on the market with the best taste and the most consistent level of CBD,” said PURA CEO Brian Shibley. “Working closely with KALY today is enabling us to rapidly diversify our cannabis sector beverage offerings and we expect this diversification to substantially contribute to continued rapid sales growth in 2019.” The management presentation regarding PURA’s 2018 growth and plans for 2019 is included in its entirety below:
PURA is the sole licensee of a patented cannabis extraction process for the purposes of infusing cannabis extracts into beverages. The company introduced its first beverage, EVERx CBD Sports Water, in 2017. The company has since introduced additional cannabis sector beverages and initiated pilot sales and marketing programs. The 2018 financial statement represents a major achievement with PURA realizing over $1 million in sales. The company reported over $1.2 million in revenue for year-end December 31, 2018 with over $500,000 in net profit.
2019 Cannabis Beverage Sales Outlook
In addition to its ongoing and growing sales of EVERx CBD Sports Water, PURA has recently announced an order worth over $1.5 million to produce a private labeled CBD water. PURA has worked with the owner of the patented extraction process which PURA has licensed for producing cannabis infused beverages, to produce a higher concentrate CBD water for the private label customer. PURA management anticipates the pilot sales of its new cannabis sector beverages to gain traction later this year and make meaningful contributions to PURA’s 2019 revenue growth.
Production Capacity Increase
With the growing sales has come pressure on PURA’s current beverage production capacity. Among other production constraint issues, PURA has been slow to deliver on direct sales from the company’s Ecommerce sales on USMJ.com (USMJ.com is a cannabis sector Ecommerce site delivered by North American Cannabis Holdings, Inc. [USOTC: USMJ]). PURA is working closely with the company’s co-packer/partner Alkame Holdings, (USOTC: ALKM) to expand production capacity and keep up with PURA’s growing sales.
2019 Target Sales
Management plans to soon publish its sales targets for 2019. The company wants to first finalize its production capacity enhancement plans in addition to further refining its estimates for sales of its new beverage products. Look for a management to publish 2019 sales targets within the first week of May.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.